Siddharth Gandhi, DO
Interventional Cardiology · Normal, ILNPI 1831226042
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,498 of the $12,426 with a category attached, or 60.3%. 27 manufacturers reported payments, led by Edwards Lifesciences at 31.6% of the total. Reporting peaked in 2023 at $4,270 and has fallen 63.5% since, to $1,558 in 2025.
Across 204 payments — averaging $60.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$4K
- Penumbra, Inc.$2K
- Medtronic$1K
- Shockwave Medical, Inc$1K
- Endologix LLC$744
- Abiomed$719
- plus $2K from 21 others
Across 4 payments — averaging $5990.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$12K
- Amgen$12K
- Novartis$213
What the payments were for
- Travel & lodging$4,89039%
- Food & beverage$7,49860%
- Education$380%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 41 | $3,926 |
| Penumbra, Inc. | 7 | $2,191 |
| Medtronic(2 entities) | 23 | $1,302 |
| Shockwave Medical, Inc | 37 | $1,126 |
| Endologix LLC | 2 | $744 |
| Abiomed | 22 | $719 |
| Abbott | 17 | $677 |
| Cardiovascular Systems Inc. | 9 | $270 |
| Johnson & Johnson | 10 | $248 |
| Asahi Intecc USA, Inc. | 2 | $184 |
| Novartis | 7 | $180 |
| Amgen | 3 | $137 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $115 |
| Boston Scientific | 2 | $114 |
| Boehringer Ingelheim | 5 | $105 |
| Inari Medical, Inc. | 1 | $97 |
| Livanova USA, Inc. | 1 | $62 |
| Atricure, Inc. | 1 | $46 |
| Cardiva Medical, Inc. | 1 | $43 |
| Genentech USA, Inc. | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| CSL Behring | 1 | $20 |
| Philips North America LLC | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Merck | 1 | $15 |
| Pfizer | 1 | $13 |
| W. L. Gore & Associates, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$2,527
- Indigo System$2,102
- Micra$702
- AFX$398
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$389
- Alto Abdominal Stent Graft System$346
- SAPIEN 3 Ultra RESILIA$311
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$172
- ASAHI PTCA Guide Wire$164
- Impella$146
- COREVALVE EVOLUT R$145
- OPTIS$128
- XARELTO$104
How this compares
$12,426 in reported general payments places this provider in the 60th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 11 | $255,596 |
| FarxigaDapagliflozin Propanediol | 118 | $134,363 |
| EliquisApixaban | 71 | $67,368 |
| JardianceEmpagliflozin | 48 | $54,138 |
| EntrestoSacubitril/Valsartan | 39 | $48,551 |
| Repatha SureclickEvolocumab | 39 | $33,051 |
| ClopidogrelClopidogrel Bisulfate | 202 | $3,668 |
| Atorvastatin Calcium | 195 | $3,591 |
| Metoprolol Succinate | 156 | $2,658 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 24 | $1,619 |
| Rosuvastatin Calcium | 83 | $1,264 |
| Prasugrel Hcl | 23 | $1,240 |
| Ezetimibe | 24 | $1,126 |
| Valsartan | 26 | $740 |
| Carvedilol | 72 | $737 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $13 | $322,96582 claims |
| Boehringer IngelheimJardiance | $105 | $54,13848 claims |
| NovartisEntresto | $180 | $48,55139 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Normal
- Andrei PopElk Grove Village$900K
- Atman ShahChicago$788K
- Ravi RamanaPalos Park$458K
- Mahesh RajuDowners Grove$281K
- Mark RicciardiEvanston$253K
- Neal SawlaniPark Ridge$246K
- Tony de MartiniSpringfield$208K
- Bouyella ReddyMoline$172K
- David StewartChicago$169K
- Jaafer GolzarOak Lawn$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.